Abstract
In the United States, about 22,000 women will be diagnosed with ovarian cancer in 2011, and an estimated 14,000 patients will succumb to the disease [1]. Surgery and chemotherapy present the main treatment modalities, but despite the development of novel therapies, the overall 5 years survival for ovarian cancer patients with advanced disease at diagnosis remains at only about 30%. Novel therapeutic strategies are needed to prolong survival and achieve greater cure rates.
Matrix metalloproteinases (MMPs) are frequently expressed in ovarian cancer, and play an important role in the metastatic process. MMPs mediate degradation of the basement membrane as a crucial step in epithelial transformation, ovarian tumorigenesis and intraperitoneal metastasis [2]. Various preclinical and clinical studies have demonstrated that MMPs might provide a suitable therapeutic target. This review summarizes important observations regarding the expression of MMPs in ovarian cancer, their biological role, and data from clinical trials targeting MMPs in ovarian cancer patients.
Keywords: Batimastat, Clinical trial, Intraperitoneal, Ovarian cancer, Matrix metalloproteinase (MMP), Metastatic, Peptomimetic, Prinomastat, Serum marker, Tanomastat, Tissue Inhibitor of metalloproteinases (TIMP).
Anti-Cancer Agents in Medicinal Chemistry
Title:MMPs in Ovarian Cancer as Therapeutic Targets
Volume: 12 Issue: 7
Author(s): Amer Karam and Oliver Dorigo
Affiliation:
Keywords: Batimastat, Clinical trial, Intraperitoneal, Ovarian cancer, Matrix metalloproteinase (MMP), Metastatic, Peptomimetic, Prinomastat, Serum marker, Tanomastat, Tissue Inhibitor of metalloproteinases (TIMP).
Abstract: In the United States, about 22,000 women will be diagnosed with ovarian cancer in 2011, and an estimated 14,000 patients will succumb to the disease [1]. Surgery and chemotherapy present the main treatment modalities, but despite the development of novel therapies, the overall 5 years survival for ovarian cancer patients with advanced disease at diagnosis remains at only about 30%. Novel therapeutic strategies are needed to prolong survival and achieve greater cure rates.
Matrix metalloproteinases (MMPs) are frequently expressed in ovarian cancer, and play an important role in the metastatic process. MMPs mediate degradation of the basement membrane as a crucial step in epithelial transformation, ovarian tumorigenesis and intraperitoneal metastasis [2]. Various preclinical and clinical studies have demonstrated that MMPs might provide a suitable therapeutic target. This review summarizes important observations regarding the expression of MMPs in ovarian cancer, their biological role, and data from clinical trials targeting MMPs in ovarian cancer patients.
Export Options
About this article
Cite this article as:
Karam Amer and Dorigo Oliver, MMPs in Ovarian Cancer as Therapeutic Targets, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (7) . https://dx.doi.org/10.2174/187152012802650174
DOI https://dx.doi.org/10.2174/187152012802650174 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Method to Assess Interactivity of Drugs with Nonparallel Concentration Effect Relationships
Current Cancer Drug Targets Entropy and Enthalpy in the Activity of Tubulin-Based Antimitotic Agents
Current Chemical Biology Metallothioneins and Platinum(II) Anti-Tumor Compounds
Current Medicinal Chemistry Olive Oil and Apoptosis of Cancer Cells
Current Nutrition & Food Science Synthesis and Biological Evaluation As Microtubule-Active Agents of Several Tetrahydrofuran and Spiroacetal Derivatives
Current Medicinal Chemistry To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets Role of Flavonoids in the Prevention of Gynecological Cancers: Epidemiological Clues
Current Women`s Health Reviews Long Non-Coding RNA GAS5 in Age-Related Diseases
Current Medicinal Chemistry Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer
Current Cancer Drug Targets Functional Nanogels for Biomedical Applications
Current Medicinal Chemistry Role of Resveratrol in Modulating microRNAs in Human Diseases: From Cancer to Inflammatory Disorder
Current Medicinal Chemistry New Developments in the Management of Pleural Effusions
Current Respiratory Medicine Reviews Drug Encapsulated Nanoparticles for Treating Targeted Cells
Current Medicinal Chemistry Modified Polysaccharides as Carriers for Biomolecules
Pharmaceutical Nanotechnology Virtual Screening for the Development of Dual-Inhibitors Targeting Topoisomerase IB and Tyrosyl-DNA Phosphodiesterase 1
Current Drug Targets Induction of Synthetic Lethality by Natural Compounds Targeting Cancer Signaling
Current Pharmaceutical Design Selenium Compounds and Apoptotic Modulation: A New Perspective in Cancer Therapy
Mini-Reviews in Medicinal Chemistry PEGylation: An Overview and Recent Advances Reported in the Patent Literature
Recent Patents on Chemical Engineering Polymer Self-Assembled Nanostructures as Innovative Drug Nanocarrier Platforms
Current Pharmaceutical Design HIV-1 Vpr: Enhancing Sensitivity of Tumors to Apoptosis
Current Drug Delivery